Sarah Boyce brings to Avidity extensive experience in the life sciences industry, where she has built global organizations and brought to patients a number of innovative therapies, including Tegsedi®, Waylivra®, Soliris®, Gleevec® and Tasigna®. She most recently served as President and a member of the board of directors of Akcea Therapeutics, where she led commercialization of the company’s rare disease products. Prior to joining Akcea, Sarah held multiple executive-level roles at leading pharma and biotech companies including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche. The Healthcare Technology Report has named Sarah one of their 25 Biotech CEOs for 2022 for her work in “advancing research and bringing breakthrough drugs and treatments to market.” She holds a B.S. degree from the University of Manchester in England.
Year appointed: 2019